Market Cap 844.94M
Revenue (ttm) 55.25M
Net Income (ttm) -334.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -605.12%
Debt to Equity Ratio -0.51
Volume 597,074
Avg Vol 1,307,968
Day's Range N/A - N/A
Shares Out 70.94M
Stochastic %K 90%
Beta 0.45
Analysts Strong Sell
Price Target $20.50

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 742 8466
Address:
100 Campus Drive, Suite 102, Florham Park, United States
Morrito23
Morrito23 Aug. 25 at 5:02 PM
$PHAT Flat…but decent volume so far. I think we are starting to see the start of our next move up. But not before the sneaky tutes cover their shares. This should be about the average price of where they really starting shorting last year.
1 · Reply
Withermania
Withermania Aug. 24 at 5:28 PM
$PHAT The ride is just getting started. Company has a very bright future with a GI drug far superior to anything on the market. With their market access, PHAT would be a no brainer acquisition for a larger pharma player that’s seeing their legacy PPI drug get crushed by generics. PHAT leadership adding a Chief Legal Officer with expertise in biotech M&A right after the patent issue was solved is also very bullish.
0 · Reply
Sfgiant5
Sfgiant5 Aug. 23 at 4:08 PM
$PHAT On the Yahoo board someone mentioned that the patent on the Voquezna reformulation until 2044 was granted. I did not see that referenced on the orange book yet or on the USPTO site. Anybody else see this patent issued and have a patent reference?
1 · Reply
GrayHairGus
GrayHairGus Aug. 22 at 8:57 PM
$PHAT up nicely on my position (40k shares) so time to evaluate positives/negatives: Positives 1)healthy sales curve 2)only drug in class with first competitor a year off 3)those two factors make it a takeover target 4)large short ratio and breakout on chart make a melt up a real possibility (REAL possibility, not the nonsense constantly spewed on these threads Negatives 1)fairly large debt load 2)recent executive shakeup kind of a head scratcher 3) current EV (~$1.3B now) is stretchy for a company that won’t make a profit until it hurdles its $400M spend rate. I’m holding for now…
2 · Reply
fgggggggg
fgggggggg Aug. 22 at 8:45 PM
$PHAT the script chart is absolutely beautiful.
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Aug. 22 at 8:19 PM
$PHAT there it is. Break through that previous rejection and $15-16 minimum. With odds of $19-20 try looking good.
0 · Reply
wholelottagreen
wholelottagreen Aug. 22 at 7:56 PM
$PHAT what are the odds this company gets bought out in the next year?
1 · Reply
IFeelLucky812
IFeelLucky812 Aug. 22 at 7:44 PM
$PHAT tutes needed buy back their shares, now she can run again. $20 soon!
0 · Reply
Ecryder
Ecryder Aug. 22 at 7:31 PM
$PHAT and Ive sweated for so long on this stock the ups and of course the downs…today is so sweet
0 · Reply
Morrito23
Morrito23 Aug. 22 at 7:29 PM
$PHAT This aged poorly and I’m here for it.
0 · Reply
Latest News on PHAT
Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 17, 2025, 8:00 AM EDT - 4 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX


Phathom Pharmaceuticals Announces Leadership Succession

Apr 1, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals Announces Leadership Succession


Phathom Pharma Is A Buy Before July PDUFA

Jan 1, 2024, 6:41 AM EST - 1 year ago

Phathom Pharma Is A Buy Before July PDUFA


Morrito23
Morrito23 Aug. 25 at 5:02 PM
$PHAT Flat…but decent volume so far. I think we are starting to see the start of our next move up. But not before the sneaky tutes cover their shares. This should be about the average price of where they really starting shorting last year.
1 · Reply
Withermania
Withermania Aug. 24 at 5:28 PM
$PHAT The ride is just getting started. Company has a very bright future with a GI drug far superior to anything on the market. With their market access, PHAT would be a no brainer acquisition for a larger pharma player that’s seeing their legacy PPI drug get crushed by generics. PHAT leadership adding a Chief Legal Officer with expertise in biotech M&A right after the patent issue was solved is also very bullish.
0 · Reply
Sfgiant5
Sfgiant5 Aug. 23 at 4:08 PM
$PHAT On the Yahoo board someone mentioned that the patent on the Voquezna reformulation until 2044 was granted. I did not see that referenced on the orange book yet or on the USPTO site. Anybody else see this patent issued and have a patent reference?
1 · Reply
GrayHairGus
GrayHairGus Aug. 22 at 8:57 PM
$PHAT up nicely on my position (40k shares) so time to evaluate positives/negatives: Positives 1)healthy sales curve 2)only drug in class with first competitor a year off 3)those two factors make it a takeover target 4)large short ratio and breakout on chart make a melt up a real possibility (REAL possibility, not the nonsense constantly spewed on these threads Negatives 1)fairly large debt load 2)recent executive shakeup kind of a head scratcher 3) current EV (~$1.3B now) is stretchy for a company that won’t make a profit until it hurdles its $400M spend rate. I’m holding for now…
2 · Reply
fgggggggg
fgggggggg Aug. 22 at 8:45 PM
$PHAT the script chart is absolutely beautiful.
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Aug. 22 at 8:19 PM
$PHAT there it is. Break through that previous rejection and $15-16 minimum. With odds of $19-20 try looking good.
0 · Reply
wholelottagreen
wholelottagreen Aug. 22 at 7:56 PM
$PHAT what are the odds this company gets bought out in the next year?
1 · Reply
IFeelLucky812
IFeelLucky812 Aug. 22 at 7:44 PM
$PHAT tutes needed buy back their shares, now she can run again. $20 soon!
0 · Reply
Ecryder
Ecryder Aug. 22 at 7:31 PM
$PHAT and Ive sweated for so long on this stock the ups and of course the downs…today is so sweet
0 · Reply
Morrito23
Morrito23 Aug. 22 at 7:29 PM
$PHAT This aged poorly and I’m here for it.
0 · Reply
BioTechChap
BioTechChap Aug. 22 at 7:22 PM
$PHAT No sign of phlatening!
0 · Reply
PolymathMan
PolymathMan Aug. 22 at 7:08 PM
$PHAT Glad this is final getting backed off……….congrats everyone
0 · Reply
RonIsWrong
RonIsWrong Aug. 22 at 6:45 PM
This is what I really enjoy, and am often quite proud of. My $PHAT entries were good, and here I am up 30ish percent in a short period of time. Timing is really key. I generally feel like these types of plays are not that difficult if you are patient. I've tried to post them on ST, not just to boast (lol) but really to try to explain how I look for trades and how they can work out. Obviously, if I was braver, I would have been buying PHAT before the big move up, but that was a real unknown: we didn't know if the citizen's petition would actually pay off. It did. But that's okay, there are still profits to be made after big moves.
1 · Reply
Lolichocho
Lolichocho Aug. 22 at 5:36 PM
$PHAT love to see it getting back where it belongs. Wrap this year up and sell this puppy.
0 · Reply
RonIsWrong
RonIsWrong Aug. 22 at 5:07 PM
$PHAT this continuation looks good
2 · Reply
Joe_90_
Joe_90_ Aug. 22 at 4:42 PM
$PHAT now, it's time for pub, two days this week have a good weekend all
0 · Reply
Morrito23
Morrito23 Aug. 22 at 4:40 PM
$PHAT Big sell orders set at 12. I don’t think we will break it today, but if we do…color me impressed.
1 · Reply
Jacobi
Jacobi Aug. 22 at 4:39 PM
$PHAT Buh Bye
0 · Reply
Walleyeslayer
Walleyeslayer Aug. 22 at 3:46 PM
$PHAT if you flip Pennie’s sell it but for the rest of us we shall make some dough. Early in the quarter so we’ll either see the bounce or maybe right to 15. GL
0 · Reply
stocksUP59
stocksUP59 Aug. 22 at 3:03 PM
$PHAT Launch is HEATING UP! Weekly TRx: For the week ending 8/15/25, Voquezna normalized TRx were 11,188 (+5% wk/wk, +9% mo/mo). Non-normalized TRx were 9,453. Refills @ 55% TRx
2 · Reply
Withermania
Withermania Aug. 22 at 2:53 PM
$PHAT this is ramping up perfectly. Interest rates going lower, scripts skyrocketing, expenses going down…this is headed back to $17+…that’s when the BO offer comes in. Buying now is still a STEAL
0 · Reply
sunset_PARK
sunset_PARK Aug. 22 at 12:56 PM
$PHAT, anyone got the latest weekly script chart to share?
1 · Reply